Physician profile
Peter R Brookmeyer
NPI 1881658839
$3,072.82
in general payments reported to CMS, 2019-2025
15 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $152 · 2021: $309 · 2022: $705 · 2023: $428 · 2024: $289 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,046.77 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $839.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $369.35 | 2019-2025 | Pifeltro, Capvaxive, Prevymis |
| Abbvie INC. | $260.68 | 2021-2025 | Dalvance, Teflaro |
| Tetraphase Pharmaceuticals, INC. | $92.42 | 2019-2020 | |
| Janssen Biotech, INC. | $90.11 | 2019 | |
| Astellas Pharma US INC | $85.65 | 2022-2023 | Cresemba |
| Allergan, INC. | $80.51 | 2019-2020 | |
| Theratechnologies INC. | $62.87 | 2019 | |
| Shionogi INC | $47.89 | 2022 | |
| Janssen Scientific Affairs, LLC | $23.99 | 2019 | |
| Vyera Pharmaceuticals, LLC | $22.81 | 2022 | |
| Insmed, INC. | $19.01 | 2023 | Arikayce |
| Ossur Americas, INC. | $18.46 | 2025 | |
| La Jolla Pharmaceutical Company | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Brookmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.